GLP-1s and type 2 diabetes remission: control is not the same outcome

Define remission before comparing success rates

The 2021 international consensus proposes remission as an HbA1c below 6.5%, measured at least three months after stopping glucose-lowering pharmacotherapy. That definition separates a sustained off-medication state from good glucose control during treatment. It applies to type 2 diabetes and should not be casually extended to other diabetes types. When a headline says a GLP-1 reversed diabetes, ask for the laboratory threshold, the testing date and the medicines being taken at that time. Without those details, the word may be describing a different outcome. A valuable improvement in blood sugar does not need to be mislabeled to matter.^[1]

Why a normal A1c on treatment does not answer the remission question

GLP-1 medicines can lower glucose while a person takes them. The consensus specifically says drug-independent remission cannot be determined while glucose-lowering treatment continues, even if a GLP-1 is being used for weight or cardiovascular reasons. That is a classification issue, not a reason to stop a medicine to qualify for a label. A clinician may reasonably continue treatment because its benefits are important. A patient whose A1c is excellent on therapy has achieved a meaningful treatment outcome, even when remission cannot be diagnosed. Your care plan should prioritize health and the reasons for treatment, rather than chase terminology through unsupervised withdrawal.^[1]

SURPASS-2 measured glucose control during active treatment

SURPASS-2 randomized 1,879 people with type 2 diabetes to tirzepatide at one of three doses or semaglutide 1 mg weekly for forty weeks, with background metformin. It compared the change in HbA1c while patients followed those treatment strategies. The trial found larger average reductions with tirzepatide, but it was not a test of remaining below the diabetes threshold after all glucose-lowering drugs were stopped. That distinction remains true even for participants reaching a very low A1c. An on-treatment glycemic target, an off-treatment remission endpoint and a cure claim are three different statements. Do not translate the first into the other two.^[2] For the actual active-treatment comparison, read our SURPASS-2 A1c guide.

DiRECT provides a different kind of remission evidence

The original DiRECT trial tested an intensive weight-management program delivered through primary care, with protocol-led medication withdrawal and structured support. At twelve months, remission under that study’s definition occurred in 46% of the intervention group and 4% of controls. It was not a GLP-1 drug trial, and its original definition required at least two months off antidiabetic medication, whereas the later consensus uses at least three months. Both differences matter. DiRECT establishes that remission can occur in a defined clinical program; its percentage cannot be used as the expected remission rate from semaglutide, tirzepatide or a commercial telehealth package.^[3]

The five-year extension shows why the time point matters

The DiRECT extension reported that eleven of eighty-five extension participants with five-year data, or 13%, were in remission at that point. Among those in remission at year two, 26% remained in remission at year five. The extension involved a selected continuing group, so its denominator and follow-up structure should remain visible. It is not appropriate to compare its 13% directly with an on-drug A1c rate from another trial and conclude one intervention works better. The useful lesson is that remission has a duration and can end. A study should say whether it counted current remission, sustained remission or any period of remission.^[4] A separate withdrawal question is covered in our weight-regain-after-stopping guide; weight change alone does not diagnose diabetes remission.

Remission is not a promise of permanent cure

NIDDK explains why remission is a more careful term than cure: diabetes can recur, and the underlying susceptibility does not simply disappear when glucose improves. The patient still needs a follow-up plan. An off-medication result at one time point is different from proof of lifelong freedom from diabetes, and neither a testimonial nor a provider’s percentage can establish that future. Ask how a proposed program defines its success and how it handles recurrence or the need to restart treatment. I would be especially cautious about advertisements that use reversal without a clear definition, a medication record or a stated observation period.^[5]

Build a monitoring plan instead of a do-it-yourself stopping test

If remission is an appropriate topic for your situation, ask your diabetes clinician what evidence would support it and how medicines, laboratory tests and complication checks would be managed. Bring the full prescription list, recent results and the reason each medicine is used. A GLP-1 may have a purpose beyond a single glucose value, which must remain part of the decision. Do not stop treatment or cancel refills to run your own test of whether diabetes has gone away. Continuing care matters even after remission. A written plan should explain who orders follow-up testing, what prompts reassessment and who coordinates treatment if glucose rises again.^[5] When several diabetes medicines are involved, review our combination-treatment and low-blood-sugar guide as preparation for the clinician discussion.

Evaluate services on coordination, not a remission guarantee

A provider review can help you compare records sharing, follow-up access, insurance support and total costs. It cannot tell you which company will put your diabetes into remission. Ask whether the service actually manages established type 2 diabetes or only offers weight-management prescribing, and how your regular diabetes team remains involved. Sesame Care and LifeMD can be investigated as published care arrangements, with their exact clinical scope confirmed before enrollment. A lower package price does not answer the coordination question. My assessment is that GLP-1 evidence supports discussing glucose control and other appropriate outcomes; a separate, properly measured off-medication result is needed before calling the outcome remission.^[2] For a care-shopping starting point, read our Sesame Care review and confirm whether the clinician can manage your actual diabetes needs. Compare the scope described in our LifeMD review with the role of your existing diabetes team.

Explore relevant provider reviews

Use these reviews to compare the published services and terms. Inclusion is a research starting point, not a recommendation for treatment.

Continue your research

• GLP-1 medicines and psoriasis: promising signals, uneven evidence
• GLP-1 taste changes and dry mouth: separate the symptoms